Updates are available Correction dated 2025-03-15
Click to view Correction: https://doi.org/10.1186/s40168-025-02069-y
-
Authors
Chandrasekaran, Prabha
Krausz, Máté
Han, Yu
Mitsuiki, Noriko
Gabrysch, Annemarie
Nöltner, Christina
Proietti, Michele
Heller, Theo
Grou, Caroline
Calderon, Virginie
Subramanian, Poorani
Jones, Drew R.
Siu, Yik
Deming, Clayton
Conlan, Sean
Holland, Steven M.
Segre, Julia A.
Uzel, Gulbu
Grimbacher, Bodo
Falcone, Emilia Liana https://orcid.org/0000-0002-5486-1549
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 2 January 2025
First Online: 11 February 2025
Change Date: 2 March 2025
Change Type: Update
Change Details: The original online version of this article was revised: At the end ofIn the Abstract, Conclusions section “ta” should be “targets”.
Change Date: 15 March 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40168-025-02069-y
Declarations
:
: NIH cohortHealthy individuals and patients with CTLA4-D provided informed consent in accordance with the Declaration of Helsinki and were enrolled into the National Institute of Allergy and Infectious Diseases (NIAID) Institutional Review Board (IRB)-approved protocol 93-I-0119 — Detection and Characterization of Host Defense Defects (ClinicalTrials.gov: ), a prospective longitudinal observational cohort study.CCI cohortHealthy individuals and patients with CTLA4-D or CVID were recruited; patient consent was collected by the treating physicians, and samples were processed at the Uniklinik Freiburg under the ethics-approved protocols 526/14, 295/13_140782, and 60/18.
: Not applicable.
: The authors declare no competing interests.
